Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.34 |
| ▸ | FEN1 | P39748 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12823948 | 0.94 | ALOX5AP (0.36) | FFAR4ALOX5APFEN1FFAR1 | |
| SCHEMBL12821292 | 0.92 | ADRB2 (0.35) | FFAR4ALOX5APFEN1NR1H4FFAR1 | |
| SCHEMBL12717484 | 0.92 | S1PR1 (0.33) | FFAR4ALOX5APFEN1NR1H4FFAR1 | |
| SCHEMBL12737456 | 0.91 | ALOX5AP (0.35) | FFAR4ALOX5APFEN1NR1H4FFAR1 | |
| SCHEMBL14766704 | 0.90 | ALOX5AP (0.34) | FFAR4ALOX5APFEN1NR1H4FFAR1 | |
| SCHEMBL12719496 | 0.90 | ALOX5AP (0.38) | ALOX5APFEN1CCNCCDK8 | |
| SCHEMBL12822740 | 0.90 | ALOX5AP (0.38) | ALOX5APFEN1CCNCCDK8 | |
| SCHEMBL13586477 | 0.89 | PTGS2 (0.39) | FFAR4ALOX5APFEN1NR1H4FFAR1 | |
| SCHEMBL12823702 | 0.89 | FFAR4 (0.37) | FFAR4ALOX5APFEN1 | |
| SCHEMBL12717914 | 0.89 | S1PR1 (0.34) | FFAR4ALOX5APFEN1HRH3NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| WO-2009150966-A1 | TETRACYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | チッソ株式会社 (JP) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | FFAR4 546/4885ALOX5AP 1673/4885FEN1 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.